• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Biomea Fusion, Inc. - Common Stock (NQ: BMEA )

    4.230 +0.150 (+3.68%)
    Streaming Delayed Price Updated: 4:00 PM EST, Dec 20, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 858,970
    Open 4.020
    Bid (Size) 4.220 (2)
    Ask (Size) 4.400 (6)
    Prev. Close 4.080
    Today's Range 3.960 - 4.280
    52wk Range 3.610 - 20.21
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
    Biomea Fusion's COVALENT-111 study shows icovamenib reduces HbA1c significantly in T2D patients, with no safety concerns or drug interactions. 
    Via Benzinga

    Performance

    YTD
    -71.17%
    -71.17%
    1 Month
    -33.70%
    -33.70%
    3 Month
    -48.73%
    -48.73%
    6 Month
    -23.78%
    -23.78%
    1 Year
    -70.44%
    -70.44%

    More News

    Read More
    Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
    Via Benzinga
    Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
    Via Benzinga
    FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
    Via Benzinga
    Exposures Product Safety
    Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
    Via Benzinga
    Topics Economy
    Exposures Interest Rates
    IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
    Via Benzinga
    FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
    From Biomea Fusion, Inc.
    Via GlobeNewswire
    BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024
    Via InvestorPlace
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.